Genetic Engineering & Biotechnology News (GEN) has retained its position as the premier biotech publication since its launch in 1981. GEN publishes a print edition monthly and has additional exclusive editorial content online, including news and analysis as well as webinars, videos, and polls. GEN's unique news and technology focus covers the entire bioproduct life cycle, including drug discovery, early-stage R&D, applied research (e.g., omics, biomarkers, and diagnostics), bioprocessing, and commercialization.
GEN's print magazine, which also can easily be accessed online, includes feature articles on emerging technologies, product roundups, in-depth overviews from key scientific and bioindustry meetings, and industry-standard tutorials and technical articles on drug discovery, bioprocessing, and assay technologies.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
Artificial intelligence is advancing quickly into laboratory operations, which is why thinking about the quality and integrity of the supporting data early on is important. In regulated environments, that means understanding where the data came from, how it changes, and how AI-generated insights or recommendations can be traced, reviewed, trusted, and ultimately defended.
In this GEN podcast, LabVantage’s Gary Stimson digs into what it takes to build a data foundation for trustworthy AI. The discussion covers concepts like data lineage, traceability, explainability and governance, and the importance of audit-ready laboratory operations. It also looks at the role of intended use, ongoing monitoring, and human review in deploying AI responsibly.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
19 Aug 2026
Small Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale-Up, and Sustainability
Small molecules continue to play a major part in pharmaceutical development, but increasing molecular complexity, accelerated timelines, and evolving manufacturing and regulatory requirements are creating new challenges for the industry.
In this GEN Podcast – part 2 in a 3-part series -- a trio of experts from SK Pharmteco discuss how CDMOs are helping biopharma companies navigate critical areas including scale-up, technology transfer, advanced manufacturing, automation, sustainability, the emergence of AI, and supply chain reliability. The discussion explores practical strategies for improving development efficiency while supporting quality, scalability, and long-term commercial success.
Guest Speakers
Steve Barr, PhD -- Head of Small Molecule Business Unit and VP Global Alliances, SK Pharmteco.
Darryl Ratty -- Executive Director of Global ESG (Environmental, Social and Governance), SK Pharmteco.
Bill Dubay -- VP, Global Research and Development, SK Pharmteco.
Moderator:
Kevin Davies, PhD, Editorial Director, GEN
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
27 Jul 2026
AI readiness in regulated laboratories
This episode establishes the broader context for AI adoption. Rather than focusing on AI tools themselves, the discussion explores what laboratories must have in place before AI can be applied responsibly.
Key discussion areas include:
Why fragmented workflows and disconnected systems limit AI effectiveness
The importance of trusted, connected laboratory data
Human-guided AI and human-in-the-loop governance
Why compliance and auditability should be built into AI-enabled workflows from the outset
Relevant reference to LabVantage CORTEX:
LabVantage CORTEX embeds AI within laboratory execution workflows so that intelligence operates within existing scientific and compliance processes, rather than as an external layer.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
21 Apr 2026
Enabling In Vivo Lentiviral Therapies: Manufacturing Strategies to Improve Purity, Scalability, and Clinical Readiness.
Lentiviral vectors are gaining momentum not just as ex vivo tools but as potential in vivo therapeutic platforms. But with that shift comes a number of manufacturing challenges, including higher doses, tighter control of impurities, greater batch consistency, and scalable processes to meet both clinical and commercial needs.
In this GEN Podcast, two experts from SK Pharmteco, a global CMO, address these challenges and lay out some best practices that guide the manufacture of lentiviral vectors with the requisite purity, robustness, and economic feasibility required for widespread clinical adoption.
Guest speakers:
Mardhani Aparajithan, Director of Manufacturing, Science and Technology, SK Pharmteco
Tatiana Nanda, PhD, CTO, Cell and Gene Therapy, SK Pharmteco
Moderator:
Kevin Davies, PhD, Editorial Director, GEN
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
11 Apr 2025
The Future of Bioinformatics: Scaling Interactive and Computational Workflows with Seqera
Sponsored by Seqera
As data volumes in life sciences continue to grow, bioinformaticians and researchers are more dependent than ever on solutions that help them streamline workflows, manage data, and scale their research. In this timely podcast, Evan Floden, CEO and co-founder of Seqera, shares how his company is addressing these needs through Nextflow—the open-source orchestrator for scalable, reproducible, and portable scientific workflows—and Seqera Platform, a unified solution for the entire scientific data lifecycle. He also discusses how Seqera has become a widely adopted solution, trusted by 13 of the top 20 pharmaceutical companies, empowering breakthroughs in drug discovery, genomics, clinical research, and.beyond.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
8 Apr 2025
Smart Vector Design for Improved Cell and Gene Therapies
In the episode, we’re talking about vector design and delivery for gene therapies. The field of cell and gene therapies is advancing, but there are still challenges with delivery vectors that need to be addressed. In this podcast, experts discuss current immunogenicity hurdles, evolving DMPK strategies, and a new generation of bioanalytical tools that are contributing to the progress in the field.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
8 Apr 2025
From Functional Genomics to Cell Therapy: The Role of CRISPR-based Gene Editing
There are an estimated 6,000 Mendelian diseases, most of which still lack cures. Gene editing is an essential technology for studies aimed at generating data about disease-causing gene mutations and networks in order to identify optimal therapeutic targets. In this episode, experts will discuss applications of gene editing to improve scientists understanding of the relationship between variant and disease in functional genomics studies. They will also talk about the Dharmacon product suite which is designed for CRISPR-based targeted editing in a wide range of cells.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
28 Mar 2025
Precision Base Editing Meets Single-Cell Multiomics to Advance Cell and Gene Therapies
In this episode, you’ll hear a group of experts discussing base editing and how the technology is helping scientists engineer powerful cell therapies for various diseases including novel CAR-T therapies and hypoimmunogenic induced pluripotent stem cells. During the discussion, they will cover the merits of the Pin-point base editing platform, which introduces gene modifications without relying on double-strand DNA breaks, as well as how TotalSeq reagents, which confirm the safety and efficiency of editing with the Pin-point platform, support single cell multiomics analysis of edited cells.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
22 Jan 2024
Cas-CLOVER: An advanced gene editing technology capable of meeting crop improvement challenges
This GENcast is the final installment in a 3-part series on Cas-CLOVER (https://demeetra.com/cas-clover/), “the proven alternative to CRISPR/Cas9,” sponsored by Demeetra AgBio. Demeetra has built extensive gene editing know-how, complementing its internally developed as well as globally sourced portfolio of intellectual property, which it transfers to its partners through simple commercial licenses with freedom to operate.
Jack Crawford, CEO of Demeetra, sat down with Dr. Leena Tripathi, Director of the Eastern Africa Hub and Leader of the Biotechnology Program at the International Institute of Tropical Agriculture (IITA), and David Norman, Senior Scientist in the Plant Systems Group at Demeetra.
They discuss how combining advanced gene editing techniques with traditional methods for plant breeding can meet the global challenges of feeding a rapidly growing population. Additionally, they discuss their brief communication in Plant Biotechnology Journal (https://demeetra.com/a-new-and-novel-high-fidelity-genome-editing-tool-for-banana-using-cas-clover/) that was published in 2023 demonstrating Cas-CLOVER as an alternative genome-editing tool to CRISPR/Cas9 by targeting MusaPDS in the banana genome.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
14 Dec 2023
The Possibilities of Cas-CLOVER and piggyBac
This GENcast is part 2 of a 3-part series on Cas-CLOVER (https://demeetra.com/cas-clover/), “the proven alternative to CRISPR/Cas9,” sponsored by Demeetra AgBio. Demeetra has built extensive gene editing know-how, complementing its internally developed as well as globally sourced portfolio of intellectual property, which it transfers to its partners through simple commercial licenses with freedom to operate.
Jack Crawford, CEO of Demeetra, sat down with Dr. Molly Duman Scheel, professor in the department of medical and molecular genetics at the Indiana University School of Medicine - South Bend, and Dr. Corey Brizzee, director of gene editing at Demeetra.
The discussion focuses on the use of advanced gene editing technologies to create scalable, and eco-friendly biopesticides as described in the panelists’ latest publications in Journal of Fungi’s special issue “Development and Utilization of Yeast Resources (https://demeetra.com/targeting-mosquitos-through-insecticidal-rnai-yeast-strain-using-cas-clover/)” and Fermentation’s special issue “Advances in Yeast Biotechnology from Genomics to Industry (https://demeetra.com/generation-of-a-culex-male-mosquito-sex-separation-rnai-yeast-strain-using-cas-clover-and-super-piggybac-engineering/).”
Panelists
“Two of the primary obstacles to using RNAi pesticides is the steep cost of production. How are you going to get it into the field, and how is it going to be stable, [gene edited] yeast solve both of these issues for us”—Dr. Molly Duman Scheel
“We wanted to make the expression as high as we could…we created a biomanufacturing platform [in yeast] with Cas-CLOVER by editing nutritional markers…this allowed for easy selection when we combined [the platform] with piggyBac to deliver the biopesticide RNAi”—Dr. Corey Brizzee
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
14 Dec 2023
Addressing Barriers in Gene Therapy
In this podcast episode, join us as we delve into addressing regulatory challenges in gene therapy with María Orío, the Head of Regulatory Affairs at Viralgen. Learn about the mission of Viralgen as a Contract Development and Manufacturing Organization specializing in Adeno-Associated Virus (AAV) gene therapy products. Uncover the unique challenges faced by the gene therapy industry, from the evolving regulatory landscape to the setting of acceptance criteria with limited available data. Learn how Viralgen addresses these challenges, leveraging historical data and innovative approaches. Gain valuable insights from the Chemistry, Manufacturing, and Controls (CMC) perspective, while learning how regulatory agencies are actively supporting sponsors in their quest for life-changing treatments.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
Contact GEN Podcasts
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of GEN Podcasts?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
